The mitochondrial kinase inhibitor dichloroacetate (DCA) has recently received attention in oncology due to its ability to target glycolysis. However, DCA molecule exhibits poor bioavailability and cellular uptake with limited ability to reach its target mitochondria. To overcome these biases, we have synthesized novel DCA-loaded compounds. The selection of the most promising therapeutic molecule was evaluated by combining in vitro assays, to test the antitumoral potential on leukemic cells, and a preliminary characterization of the molecule stability in vivo, in mice. Among the newly synthesized compounds, we have selected the multiple DCA-loaded compound 10, characterized by a tertiary amine scaffold, because it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in vivo stability. On the basis of these results, we believe that compound 10 should be considered for further preclinical evaluations for the treatment of cancers and/or other diseases characterized by altered metabolic origin.

Design, synthesis and biological characterization of novel mitochondria targeted dichloroacetate-loaded compounds with antileukemic activity

TRAPELLA, Claudio
Co-primo
;
VOLTAN, Rebecca
Co-primo
;
MELLONI, Elisabetta;TISATO, Veronica;Celeghini, C;BIANCO, Sara;FANTINATI, Anna;SALVADORI, Severo;GUERRINI, Remo;SECCHIERO, Paola;ZAULI, Giorgio
Ultimo
2016

Abstract

The mitochondrial kinase inhibitor dichloroacetate (DCA) has recently received attention in oncology due to its ability to target glycolysis. However, DCA molecule exhibits poor bioavailability and cellular uptake with limited ability to reach its target mitochondria. To overcome these biases, we have synthesized novel DCA-loaded compounds. The selection of the most promising therapeutic molecule was evaluated by combining in vitro assays, to test the antitumoral potential on leukemic cells, and a preliminary characterization of the molecule stability in vivo, in mice. Among the newly synthesized compounds, we have selected the multiple DCA-loaded compound 10, characterized by a tertiary amine scaffold, because it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in vivo stability. On the basis of these results, we believe that compound 10 should be considered for further preclinical evaluations for the treatment of cancers and/or other diseases characterized by altered metabolic origin.
2016
Trapella, Claudio; Voltan, Rebecca; Melloni, Elisabetta; Tisato, Veronica; Celeghini, C; Bianco, Sara; Fantinati, Anna; Salvadori, Severo; Guerrini, R...espandi
File in questo prodotto:
File Dimensione Formato  
Trapella et al. J Med Chem 2016.pdf

solo gestori archivio

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 2.75 MB
Formato Adobe PDF
2.75 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
ZAULI 11392-2338223 post print.pdf

accesso aperto

Descrizione: post print
Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 831.47 kB
Formato Adobe PDF
831.47 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2338223
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 22
social impact